Efficacy and safety of daratumumab, bortezomib, and dexamethasone (D-Vd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk: Updated subgroup analysis of CASTOR.

Katja Weisel from the University Medical Center Hamburg-Eppendorf discusses the efficacy and safety of daratumumab, bortezomib, and dexamethasone.<br /><br />Background: MM patients (pts) with high cytogeneti... Author: Annual-Meeting Added: 06/05/2019
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts